drugset / Trial / NCT06392152

Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar

NCT06392152

Non-randomizedCrossoverSingle-blindTreatment

Summary

Plasmodium vivax has become the predominant species in the Greater Mekong Subregion and is a major challenge for regional malaria elimination. Mass primaquine administration has played a decisive role in malaria elimination in many temperate zone countries, but its efficacy in tropical areas remains to be evaluated. This study aims to assess the efficacy of targeted primaquine mass treatment (TPT) for eliminating P. vivax malaria in northern Myanmar.

Timeline

Start
2019-07-01
Primary completion
2024-03-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Primaquine Small molecule 0.25 mg/kg